Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

The US BLS reports that the annual median salary for interpreters and translators jumped 5% in 2024, despite a slowdown in ...

UBS maintained its Buy rating with a steady target of $80, noting improved revenue growth estimates and the successful adoption of Kokai. These developments reflect a positive shift in The Trade ...

The Seattle-based company also reported strong sales growth for its prominent cloud computing arm Amazon ... Donald Trump’s tariffs and consumer spending clouded Amazon’s outlook. Trump’s erratic ...

If you're feeling antsy at work and want a new role, first consider factors such as the strength of your industry and the ...

Today, Zacks Equity Research discusses Cintas Corp. CTAS, APi Group Corp. APG and Bright Horizons Family Solutions Inc. BFAM ...

Its April 2025 Macro Poverty Outlook report projects government expenditure to stagnate through 2027. It slashed its projections for government consumption growth from 4.2 percent (2025 ...

Despite a challenging biopharmaceutical environment, Ligand Pharmaceuticals Inc (LGND) reports significant revenue growth and ...

The Class of 2025 faces a job market shaped by AI, inflation and hiring shifts. Learn which industries are growing, what ...

The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%.

Nevertheless, The Trade Desk has factored these conditions into its outlook for the second quarter ... surpassing analyst expectations by 7%. This growth was attributed to the successful adoption ...